Research Article

Endovascular treatment experience in acute ischemic stroke

Hacı Ali Erdoğan¹, İbrahim Acır²* and Vildan Yayla¹

¹Bakırköy Dr. Sadi Konuk Training and Research Hospital Istanbul, Turkey
²Başakşehir Çam and Sakura City Hospital Istanbul, Turkey

Introduction

Stroke is one of the important diseases in the world that can cause disability. In the hyperacute period, the application of mechanical thrombectomy with retractable stents in major vascular occlusions is among the proven method of treatment. According to the recent studies, mechanical thrombectomy procedure, which is recommended to be applied with iv-tPA within 4.5 hours, can be applied in suitable patients for up to 24 hours. The goal in treatment is complete recanalization (TICI 2b/3) [1]. General data and parameters of patients who underwent mechanical thrombectomy (MT) or MT + IV-tPA in our stroke center in the last 2 years were presented.

Material and methods

Patients who underwent MT or MT + IV-tPA between 2018-2019 at our stroke center were evaluated retrospectively. Demographic features and comorbid diseases of patients were listed. Symptom onset-to-gate and gate-to-puncture durations, arrival-exit mRS (Modified Rankin Score) and NIHSS (National Institutes of Health Stroke Scale) score, treatment method and degree of recanalization were listed.

Results

The number of patients who underwent MT or MT + IV-tPA was 48 (27 male/21 female). MT was applied to 29 patients, MT + bolus IV-tPA was applied to 12 patients and MT + full dose IV-tPA was applied to 7 patients. Hypertension (HT), atrial fibrillation (AF) and diabetes mellitus (DM) were the most common comorbid diseases (respectively 48%, 23% and 15%). The mean age was 66 ± 15 years, arrival mRS was 2 ± 2, arrival NIHSS score was 14 ± 5, onset-to-gate duration was 185 minutes and gate-to-puncture duration was 118 minutes.

Conclusion: The rate of recanalization, functional independence and mortality were similar to the HERMES study. It was observed a higher rate of intracranial hemorrhage in patients who received bolus or full dose IV-Tpa compared to patients who underwent MT. These results have led us to question the necessity of giving bolus or full dose IV-tPA before MT. Onset-to-gate and gate-to-puncture durations were found longer than the recommended durations. Rapid and effective management of AIS patients will provide good clinical results.

Open Access

More Information

*Address for Correspondence: İbrahim Acır, Başakşehir Çam and Sakura City Hospital Istanbul, Turkey, Tel: +905444498678; Email: iacir33@gmail.com
Submitted: April 19, 2021
Approved: April 23, 2021
Published: April 26, 2021

How to cite this article: Erdoğan HA, Acır I, Yayla V. Endovascular treatment experience in acute ischemic stroke. J Neurosci Neurol Disord. 2021; 5: 026-028.
DOI: 10.29328/journal.jnnd.1001047
ORCID: orcid.org/0000-0002-9650-8022
Copyright: © 2021 Erdoğan HA, et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Keywords: Acute stroke; Endovascular treatment

Abstract

Background and Objective: Thrombolytic and mechanical thrombectomy therapies are proven treatment methods in patients with acute stroke. Aim is to share our experience in acute stroke therapy with colleagues.

Material and methods: In this study we evaluated the patients who underwent MT or MT + IV-tPA between 2018-2019 retrospectively. Demographic features, comorbid diseases of patients, symptom onset-to-gate and symptom gate-to-puncture durations, mRS (Modified Rankin Score) and NIHSS (National Institutes of Health Stroke Scale) score, treatment method and degree of recanalization were listed.

Results: MT was applied to 29 patients, MT + bolus IV-tPA was applied to 12 patients and MT + full dose IV-tPA was applied to 7 patients. The mean age was 66 ± 15 years, arrival mRS was 2 ± 2, arrival NIHSS score was 14 ± 5, onset-to-gate duration was 185 minutes and gate-to-puncture duration was 118 minutes.

Conclusion: The rate of recanalization, functional independence and mortality were similar to the HERMES study. It was observed a higher rate of intracranial hemorrhage in patients who received bolus or full dose IV-Tpa compared to patients who underwent MT. These results have led us to question the necessity of giving bolus or full dose IV-tPA before MT. Onset-to-gate and gate-to-puncture durations were found longer than the recommended durations. Rapid and effective management of AIS patients will provide good clinical results.
2 ± 2, arrival NIHSS score was 14 ± 5, onset-to-gate duration was 185 minutes and gate-to-puncture duration was 118 minutes (Table 1). Complete or partial recanalization was achieved in the majority of patients undergoing MT or MT + IV-tPA (64%). The 24th hour NIHSS score was calculated as 12.5 on average, and the 24th hour mRS was 4 on average. Hemorrhagic transformation occurred in 73% of patients. Five of the patients who underwent thrombectomy died.

**Discussion**

According to the World Health Organization (WHO), stroke is a clinical syndrome characterized by signs and symptoms of cerebral function loss. In acute ischemic stroke (AIS), IV-tPA and MT are proven treatment methods for best clinical outcomes. Intravenous thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) is a proven method of treatment in patients presenting within the first four and a half hours with acute ischemic stroke [2,3]. In the AHA 2015 (American Heart Association 2015) guideline, endovascular treatment with stent-retriever in selected patients is class IA recommendation [4]. In addition, in DAWN and DEFUSE 3 studies, it has been shown that endovascular treatment may be beneficial in patients with proximal artery occlusion up to the 16-24 hours [5,6]. In HERMES (Effectively Reperfusion Evaluated in Multiple Endovascular Stroke) meta-analysis, the recanalization rate was 71%, while in another meta-analysis this rate was reported as 81% [7,8]. Complete recanalization (TICI2b/3) was achieved in our patient group at a rate of 64%. Functional independence was calculated as 19.5% and our mortality rate was around 10%. Our study is similar to the HERMES study in this regard. On the other hand, our study covers the short term, functional improvement after 90 days could not be evaluated.

In the DEFUSE study, the 90th day mRS and NIHSS scores of patients who underwent MT + IV-tPA were found significantly lower, and there was no significant difference in the number of patients who developed hemorrhagic transformation [6]. In our study, MT was applied to 29 patients, MT + bolus IV-tPA applied to 12 patients and MT + full dose IV-tPA was applied to 7 patients. Intracranial hemorrhage was found in 65% of patients who underwent MT, 83% of patients who underwent MT + bolus IV-tPA, and 85% of patients who underwent MT + full dose IV-tPA. According to our data, there was no significant difference in terms of the risk of intracranial hemorrhage in patients who received bolus or full dose IV-Tpa, but it was observed at a higher rate compared to patients who underwent MT. These results have led us to question the necessity of giving bolus or full dose IV-tPA before MT.

In our study, HT, AF and DM were the most common comorbid diseases in patients who underwent MT or IV-tPA + MT. Intracranial hemorrhage revealed in 82% of patients with HT, 62% of patients with AF and 85% of patients with DM. HT and DM have been identified as comorbid diseases that cause more intracranial hemorrhage. In this respect, we think that strict blood glucose and blood pressure monitoring are important.

The cause of death of 2 patients was secondary infections regardless of the procedure. We consider that the cause of death of the other 3 patients was difficult endovascular procedure due to poor vascular structure.

Success in the treatment of acute stroke is often time-dependent. Many studies have shown that symptom-needle duration is an important factor in clinical recovery [9,10]. In our study, onset-to-gate and gate-to-puncture durations were found longer than the recommended times, not statistically significant. But we think that this problem can be partially overcome by shortening the transfer durations.

**Conclusion**

The fact that the rate of intracranial bleeding was higher in patients who received bolus or full dose IV-tPA compared to patients who had only MT, showed that we should make a more careful patient selection for IV-tPA.

**Table 1:** Comparison of the groups NIHSS, mRS and processing durations.

<table>
<thead>
<tr>
<th></th>
<th>MT + IV-tPA</th>
<th>MT</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AGE</strong></td>
<td>Mean ± SD</td>
<td>Mean ± SD</td>
<td>0.941</td>
</tr>
<tr>
<td></td>
<td>Med. (Min.-Max.)</td>
<td>Med. (Min.-Max.)</td>
<td></td>
</tr>
<tr>
<td>66 ± 14</td>
<td>67 ± 16</td>
<td></td>
<td></td>
</tr>
<tr>
<td>65 (45 - 89)</td>
<td>70 (32 - 86)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ARRIVAL NIHSS</strong></td>
<td>16 ± 4</td>
<td>14 ± 6</td>
<td>0.184</td>
</tr>
<tr>
<td></td>
<td>15 (10 - 24)</td>
<td>13 (2 - 25)</td>
<td></td>
</tr>
<tr>
<td><strong>ARRIVAL mRS</strong></td>
<td>2 ± 2</td>
<td>2 ± 2</td>
<td>0.724</td>
</tr>
<tr>
<td></td>
<td>1 (0 - 5)</td>
<td>1 (0 - 5)</td>
<td></td>
</tr>
<tr>
<td>**ONSET-TO-GATE (min.)</td>
<td>136 ± 84</td>
<td>218 ± 219</td>
<td>0.512</td>
</tr>
<tr>
<td></td>
<td>120 (30 - 270)</td>
<td>150 (15 - 780)</td>
<td></td>
</tr>
<tr>
<td>**GATE-TO-PUNCTURE (min.)</td>
<td>82 ± 84</td>
<td>142 ± 255</td>
<td>0.15</td>
</tr>
<tr>
<td></td>
<td>60 (30 - 270)</td>
<td>90 (30 - 1440)</td>
<td></td>
</tr>
<tr>
<td><strong>DISCHARGE NIHSS</strong></td>
<td>17 ± 9</td>
<td>12 ± 6</td>
<td>0.029</td>
</tr>
<tr>
<td></td>
<td>16 (0 - 30)</td>
<td>10 (0 - 30)</td>
<td></td>
</tr>
<tr>
<td><strong>DISCHARGE mRS</strong></td>
<td>4 ± 2</td>
<td>4 ± 2</td>
<td>0.077</td>
</tr>
<tr>
<td></td>
<td>5 (0 - 6)</td>
<td>4 (0 - 6)</td>
<td></td>
</tr>
</tbody>
</table>

**References**

5. Hacke W. A new DAWN for imaging-based selection in the treat-


